Partial Splenic Embolization in a Patient with Hemophilia A and Severe Thrombocytopenia: A Case Report

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-03-26 DOI:10.3390/hematolrep16020019

Tomofumi Nakamura, Mitsuhiro Uchiba, Hirotomo Nakata, Takao Mizumoto, Toru Beppu, Shuzo Matsushita

{"title":"Partial Splenic Embolization in a Patient with Hemophilia A and Severe Thrombocytopenia: A Case Report","authors":"Tomofumi Nakamura, Mitsuhiro Uchiba, Hirotomo Nakata, Takao Mizumoto, Toru Beppu, Shuzo Matsushita","doi":"10.3390/hematolrep16020019","DOIUrl":null,"url":null,"abstract":"We report a patient with hemophilia A who underwent partial splenic embolization (PSE) for severe thrombocytopenia secondary to portal hypertension-induced splenomegaly, resulting in a stable long-term quality of life. The patient was diagnosed with hemophilia A and unfortunately contracted human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) from blood products. He subsequently developed progressive splenomegaly due to portal hypertension from chronic HCV, resulting in severe thrombocytopenia. PSE was performed because he had occasional subcutaneous bleeding and needed to start interferon (IFN) and ribavirin (RBV) treatment for curing his HCV infection at that time. His platelet counts increased, and no serious adverse events were observed. Currently, he continues to receive outpatient treatment, regular factor VIII (FVIII) replacement therapy for hemophilia A, and antiretroviral therapy for HIV infection. Vascular embolization has been reported to be an effective and minimally invasive treatment for bleeding in hemophilia patients. PSE also provided him with a stable quality of life without the side effects of serious infections and thrombocytopenia relapses. We conclude that PSE is a promising therapeutic option for patients with hemophilia A.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/hematolrep16020019","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

We report a patient with hemophilia A who underwent partial splenic embolization (PSE) for severe thrombocytopenia secondary to portal hypertension-induced splenomegaly, resulting in a stable long-term quality of life. The patient was diagnosed with hemophilia A and unfortunately contracted human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) from blood products. He subsequently developed progressive splenomegaly due to portal hypertension from chronic HCV, resulting in severe thrombocytopenia. PSE was performed because he had occasional subcutaneous bleeding and needed to start interferon (IFN) and ribavirin (RBV) treatment for curing his HCV infection at that time. His platelet counts increased, and no serious adverse events were observed. Currently, he continues to receive outpatient treatment, regular factor VIII (FVIII) replacement therapy for hemophilia A, and antiretroviral therapy for HIV infection. Vascular embolization has been reported to be an effective and minimally invasive treatment for bleeding in hemophilia patients. PSE also provided him with a stable quality of life without the side effects of serious infections and thrombocytopenia relapses. We conclude that PSE is a promising therapeutic option for patients with hemophilia A.

查看原文本刊更多论文

血友病 A 和严重血小板减少症患者的部分脾栓塞：病例报告

我们报告了一名 A 型血友病患者因门静脉高压引起的脾肿大继发严重血小板减少而接受部分脾栓塞术（PSE）治疗的情况，该患者长期生活质量稳定。患者被诊断为 A 型血友病，并不幸从血制品中感染了人类免疫缺陷病毒（HIV）、乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）。随后，他因慢性 HCV 引起的门静脉高压而出现进行性脾肿大，导致血小板严重减少。由于他偶有皮下出血，且当时需要开始干扰素（IFN）和利巴韦林（RBV）治疗以治愈 HCV 感染，因此对他进行了 PSE。他的血小板计数有所增加，没有发现严重的不良反应。目前，他仍在接受门诊治疗、A 型血友病的常规因子 VIII (FVIII) 替代治疗和 HIV 感染的抗逆转录病毒治疗。据报道，血管栓塞是治疗血友病患者出血的一种有效的微创疗法。PSE 还为他提供了稳定的生活质量，没有严重感染和血小板减少复发的副作用。我们的结论是，PSE 对 A 型血友病患者来说是一种很有前景的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.